To evaluate the impact of bone morphogenetic protein-2 (BMP-2) augmentation on radiographic bone consolidation and implant survivorship in revision total hip arthroplasty (THA) for severe acetabular defects, highlighting its potential significance in improving surgical outcomes.
Key Findings:
83% of hips showed more than 50% radiographic bone consolidation at final follow-up.
No cases of graft resorption were observed.
Implant survivorship was 90% at 6 years and 70% at 10 years when defined by all-cause reoperation.
Survivorship was 90% at both time points when defined by acetabular loosening.
Mean Oxford Hip Score among 13 hips was 35 at a mean of 84 months.
28% of hips experienced postoperative complications.
Interpretation:
BMP-2 augmentation appears to enhance bone consolidation and midterm implant survivorship in revision THA for severe acetabular defects, although further studies are necessary to confirm these findings.
Limitations:
Retrospective study design, which may introduce bias.
Small sample size limits generalizability.
Lack of a control group makes it difficult to draw definitive conclusions.
Absence of preoperative patient-reported outcomes limits understanding of baseline function.
No cost-effectiveness analysis was performed.
Single-surgeon experience at a tertiary referral center may not reflect broader practice.
Conclusion:
BMP-2 augmentation is associated with positive outcomes in revision THA for severe acetabular defects, warranting further investigation into its safety and efficacy to validate these promising results.
